GlassScriptPhysician profile
Adam Banks
NPI 1992061758
$37,606.28
in general payments reported to CMS, 2019-2025
25 companies · $2,828 in 2025
The $2,828 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $6,343 · 2021: $599 · 2022: $2,867 · 2023: $2,676 · 2024: $3,410 · 2025: $2,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,769 · Travel and Lodging: $3,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,768.92 |
| Travel and Lodging | $3,144.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $24,349.18 | 2019-2020 | |
| Abbott Laboratories | $3,473.96 | 2022-2025 | Triclip, Navitor, Mitraclip |
| Abiomed | $3,292.83 | 2021-2025 | Impella |
| Edwards Lifesciences Corporation | $1,982.36 | 2019-2024 | Sapien 3 Ultra Resilia, Pascal |
| Medtronic, INC. | $1,829.65 | 2022-2024 | Corevalve Evolut R, Onyx Frontier, Symplicity G3 |
| Boston Scientific Corporation | $595.57 | 2023-2025 | Watchman Access System, Watchman, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $356.59 | 2022-2025 | Camzyos, Eliquis |
| Stryker Corporation | $272.02 | 2025 | Flowtriever |
| Philips North America LLC | $200.50 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $197.11 | 2021-2025 | |
| Heartflow, INC. | $168.92 | 2025 | |
| Amgen INC. | $158.71 | 2021-2025 | Repatha |
| Inari Medical, INC. | $139.35 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cardiovascular Systems INC. | $106.04 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $102.63 | 2023-2024 | Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.25 | 2024-2025 | Lifevest |
| Pfizer INC. | $51.40 | 2021-2024 | |
| Biosense Webster, INC. | $49.14 | 2025 | Carto 3 |
| Chiesi USA, INC. | $48.24 | 2023-2024 | Kengreal, Cleviprex |
| Cleerly, INC. | $41.69 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Angiodynamics, INC. | $39.37 | 2025 | Micro Access |
| Novo Nordisk INC | $29.37 | 2025 | Wegovy |
| Bolton Medical INC | $26.53 | 2023 | Treo Abdominal Stent-Graft System |
| Janssen Pharmaceuticals, INC | $22.00 | 2022 | |
| W. L. Gore & Associates, INC. | $14.87 | 2024 | Gore Tag Conformable Thoracic Endoprosthesis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Banks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.